Literature DB >> 15962387

Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation.

Xiao-Mou Peng1, Lin Gu, Xue-Juan Chen, Jian-Guo Li, Yang-Su Huang, Zhi-Liang Gao.   

Abstract

AIM: To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.
METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control. To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CD-PCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection.
RESULTS: The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to 10 micromol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain independent of the amount of templates and the number of PCR cycles. Its detection limit was 10(3) copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg.
CONCLUSION: Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962387      PMCID: PMC4315973          DOI: 10.3748/wjg.v11.i23.3614

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 2.  The core promoter of hepatitis B virus.

Authors:  A Kramvis; M C Kew
Journal:  J Viral Hepat       Date:  1999-11       Impact factor: 3.728

3.  Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.

Authors:  S A Whalley; D Brown; C G Teo; G M Dusheiko; N A Saunders
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 4.  Viral breakthrough during lamivudine therapy for chronic hepatitis B.

Authors:  Nancy Leung
Journal:  Intervirology       Date:  2003       Impact factor: 1.763

5.  Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B.

Authors:  Hiroshi Yotsuyanagi; Kunihiko Hino; Eiichi Tomita; Joji Toyoda; Kiyomi Yasuda; Shiro Iino
Journal:  J Hepatol       Date:  2002-09       Impact factor: 25.083

Review 6.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

7.  Hepatitis B virus: prevalence of precore/core promoter mutants in different clinical categories of Indian patients.

Authors:  S S Gandhe; M S Chadha; A M Walimbe; V A Arankalle
Journal:  J Viral Hepat       Date:  2003-09       Impact factor: 3.728

8.  Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy.

Authors:  Kyun-Hwan Kim; Kwang-Hee Lee; Hye-Young Chang; Sang Hoon Ahn; Shuping Tong; Young Joon Yoon; Baik L Seong; Soon Il Kim; Kwang-Hyub Han
Journal:  J Med Virol       Date:  2003-11       Impact factor: 2.327

9.  Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.

Authors:  Marie Matsuda; Fumitaka Suzuki; Yoshiyuki Suzuki; Akihito Tsubota; Norio Akuta; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Junko Satoh; Kimiko Takagi; Mariko Kobayashi; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2004-01       Impact factor: 7.527

10.  Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis.

Authors:  Manna Zhang; Yuewen Gong; Carla Osiowy; Gerald Y Minuk
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.